More about

Heart Failure

News
August 05, 2020
5 min read
Save

ACC: Cardiologists can use novel therapies to lower CV risk in type 2 diabetes

ACC: Cardiologists can use novel therapies to lower CV risk in type 2 diabetes

Cardiologists can use SGLT2 inhibitors and GLP-1 receptor agonists to help reduce risk for major adverse CV events in patients with type 2 diabetes, according to an expert consensus decision pathway from the American College of Cardiology.

News
August 05, 2020
3 min read
Save

New research widens continuum of risk associated with PVR in pulmonary hypertension

New research widens continuum of risk associated with PVR in pulmonary hypertension

New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in patients at risk for pulmonary hypertension undergoing right heart catheterization.

News
August 02, 2020
1 min read
Save

Valve-in-valve TAVR confers short-term benefits in failed surgical AVR

Valve-in-valve TAVR confers short-term benefits in failed surgical AVR

Among patients with a failed surgical aortic valve, valve-in-valve transcatheter aortic valve replacement was linked to better short-term outcomes than redo surgical AVR, researchers reported.

News
July 31, 2020
2 min read
Save

Bariatric surgery demonstrates good long-term CV outcomes

Bariatric surgery demonstrates good long-term CV outcomes

Bariatric surgery demonstrated significant long-term benefits for the reduction of major adverse CV events and incident HF, according to a study published in the European Heart Journal.

News
July 30, 2020
2 min read
Save

EMPEROR-Reduced topline results: Empagliflozin beneficial in HFrEF with, without diabetes

EMPEROR-Reduced topline results: Empagliflozin beneficial in HFrEF with, without diabetes

Boehringer Ingelheim and Eli Lilly and Co. announced that the SGLT2 inhibitor empagliflozin to treat patients with HF with reduced ejection fraction, with and without diabetes, met its primary endpoint in the phase 3 EMPEROR-Reduced trial.

News
July 29, 2020
2 min read
Save

Omega-3 supplementation may reduce cardiovascular risk in patients with kidney disease

Omega-3 supplementation may reduce cardiovascular risk in patients with kidney disease

For patients with kidney disease not yet on dialysis, omega-3 fatty acid supplementation led to improvements in pulse wave velocity and serum triglyceride levels, suggesting that daily use could reduce risk for cardiovascular events.

News
July 24, 2020
1 min read
Save

FDA grants breakthrough therapy designation to mavacamten

FDA grants breakthrough therapy designation to mavacamten

MyoKardia announced that the FDA has granted breakthrough therapy designation to mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy.

News
July 23, 2020
2 min read
Save

HF hospitalization in adult congenital heart disease confers 4-year elevated death risk

HF hospitalization in adult congenital heart disease confers 4-year elevated death risk

Among adults with congenital heart disease hospitalized for HF, mortality risk remained high for up to 4 years after hospital discharge, according to a study published in Circulation: Heart Failure.

News
July 22, 2020
2 min read
Save

Dapagliflozin remains safe, effective for HF irrespective of diuretic use

Dapagliflozin remains safe, effective for HF irrespective of diuretic use

Dapagliflozin for worsening HF was both safe and efficacious regardless of diuretic use or dose, according to findings from the DAPA-HF trial published in Circulation.

News
July 21, 2020
6 min read
Save

Patient sex, race may impact decision-making for heart transplant, VAD allocation

Patient sex, race may impact decision-making for heart transplant, VAD allocation

In a survey of cardiac clinicians, researchers found that neither sex nor race of a patient predicted allocation of HF therapies, although bias was observed in the form of harsher judgment of women overall, particularly for Black women.

View more